When: Trailing P/E compresses below 24x

Then: Re-engage at 7-8% of original position

When: Q3 earnings beat with raised guidance resetting multiple-expansion narrative

Then: Re-engage at 7-8% of original position

When: Breakout above $275 on volume >7M

Then: Consider re-engagement

SELL

• JNJ PEG of 4.57 with 21x forward P/E for a company expected to grow 4-6% annually over the next three years
• Q2 FCF of $7.3B (annualized $29B) should not be used as a new baseline; 2025 full-year FCF of $19.3B is the appropriate underwriting number due to Q2 seasonal high
• MACD crossed below signal with negative histogram, 10 EMA flattening, and volume declining from 7-10M to 3.93M, indicating distribution at resistance
• Price making lower highs from $274.90 to $267 range before fading
• Downside target of $228 at 200 SMA represents potential 23% drawdown from $260, with possible measured move to $200
• Net debt has doubled from $7.5B in 2023 to $28.6B today; goodwill and intangibles at $96.7B represent 15% of market cap
• Stelara patent cliff: $7-8B peak franchise representing 7% revenue exposure, starts meaningfully eroding in 2027
• Even if Darzalex and Tremfya offset 80% of Stelara loss, a $1.5B revenue hole remains
• Darzalex biosimilar pressure hits by end of decade, creating a stacked second patent cliff
• Talc settlement of $5.5 billion remains a binary event risk with potential for reversal
• The 50 SMA at $247 held only once after a 78% rally; confidence in buyers stepping in at $247, $251, or $228 on patent-cliff headlines is low
• 0.23 beta becomes a curse when macro flips; defensive names correct with the market during recessions
• Dividend Aristocrat status (64 years) and 2.05% yield are consensus expectations, creating crowding risk rather than asymmetry
• Position sizing: trim to underweight at 50% of benchmark, scale out on rallies into resistance
• Low Confidence flag in sentiment report contradicts bullish thesis

→ vs aggressive: Q2 growth of 6.6% is one quarter off a depressed comp from talc charges; structural growth rate is 4-6%, not grounds for a premium 21x multiple

→ vs aggressive: Annualizing $29B FCF from one quarter is extrapolation, not analysis; 2025 full-year FCF of $19.3B is the base case, not the $29B run rate

→ vs aggressive: MACD bearish cross and declining volume to 3.93M are textbook distribution signatures, not a 'momentum pause' to be dismissed

→ vs aggressive: $228 downside is not 'wildly pessimistic' but rather the 200 SMA functional support; measured move could reach $200, a 23% drawdown, not the 12% being dismissed

→ vs aggressive: Stelara $7-8B franchise cliff at 7% revenue exposure is not 'gradual' in a benign sense; stacking with Darzalex biosimilar pressure creates consecutive cliff risk

→ vs aggressive: Buying JNJ for its dividend means owning what every income ETF already owns, creating crowding risk rather than hidden value

→ vs aggressive: Polymarket recession odds at 8% will rise again; the 'quality compounder paradise' thesis assumes static Goldilocks macro that always changes

HOLD

• Q2 6.6% revenue growth and $7.3B FCF should not reset the structural baseline—the quarter benefited from an easy comp off the talc-charge-depressed base
• MACD cross below signal with line at positive 2.44 and histogram at minus 0.31 is momentum cooling, not failing; the 200 SMA is 14 percent below price and the 50 SMA held on July 15 test
• Patent cliff is a persistent multi-quarter drag—Stelara biosimilar pressure fully hits in 2027, with Darzalex biosimilar timeline at end of decade
• Recession odds on Polymarket are only 8 percent; JNJ's 2.05 percent dividend yield is modest by income-investor standards (crowding doesn't start until 4-5 percent)
• The 0.23 beta is a feature in Fed pause regime; AAA balance sheet and dividend provide a recovery floor
• The trader's plan is internally inconsistent—cannot simultaneously trim into strength and enter short at $228 with stop at $247
• Price is in a four-week consolidation range between $247 and $275; RSI neutral, MACD cooled but not broken; this is a stock digesting a 78 percent rally
• Recommended: trim overweight to neutral (not 50 percent underweight), sell covered calls at $275 strike for September or October expiry
• Add zone: confirmed close below $247 on expanding volume, ideally $244-246 near lower Bollinger Band
• Trim zone: rally into $268-275, particularly into Q3 earnings in October
• Maximum single-name concentration should be 8 to 10 percent of diversified portfolio

→ vs aggressive: Anchoring on Q2's strong quarter (6.6% revenue, $7.3B FCF) as a baseline reset, while dismissing the patent cliff as a structural concern. Annualizing the $29B FCF run rate at 21x multiple implies >$850B market cap valuation, which is not realistic given Stelara erosion in slow motion and Darzalex biosimilar timeline

→ vs conservative: Misreading the MACD signal—reading a yellow light (momentum cooling at positive 2.44) as red (momentum failing). Also underweighting the income story; 2.05% yield is modest and the 0.23 beta is actually favorable in Fed pause regime, not a liability